This interview with an EU-based KOL provides insights into current prescribing habits on- and off-label in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Winrevair, Tracleer, Letairis, Adcirca, Revatio, Uptravi, Remodulin, Veletri, Tyvaso, Adempas, Opsumit, Opsynvi, ralinepag and levosimendan. 

This interview was conducted on Nov. 7, 2024.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.